ALLO News and Press, Allogene Therapeutics Inc. From 10/26/22

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report third quarter 2022 fi...

Summary Caribou Biosciences' early data was good, but not that durable. However, this was the lowest dose cohort, and safety was manageable. If a higher dose, now ongoing, produces a durable response, this stock will likely go up. Caribou Biosciences ( CRBU ), founde...

New Survey Focused on Access Limitations of Approved Autologous CAR T Therapies Reveals Only 50% of Eligible Cancer Patients Receive Treatment Increased Patient Demand, Manufacturing Capacity and Time to Treatment Highlighted as the Top Three Challenges Facing Future CAR T Adoption ...

Allogene Therapeutics ( NASDAQ: ALLO ) has i nitiated the phase 2 ALPHA2 trial of ALLO-501A , an allogeneic chimeric antigen receptor T cell (AlloCAR T) therapy, for relapsed/refractory large B-cell lymphoma. The stock is up 12% in after-hours trading. The...

ALPHA2 Trial, Evaluating ALLO-501A in Relapsed/Refractory Large B Cell Lymphoma Patients, is Designed to Leverage the Ease and Convenience of a Single Dose of ALLO-501A Protocol Supported by Clinical and Translational Data from Phase 1 Trial Indicating Deep Responses are Achievable ...

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to present at the ...

The shares of clinical-stage immuno-oncology company Allogene Therapeutics, Inc. ( NASDAQ: ALLO ) fell sharply on Wednesday after the company announced that French pharma group Servier informed its decision to discontinue the collaboration for CD19-directed product candidates. ...

Summary Allogene has potential to have the first pivotal phase 2 study using its allogeneic CAR-T known as ALLO-501A for the treatment of patients with non-Hodgkin's Lymphoma. Trial results are to be released from several long-term follow-up studies including ALPHA, ALPHA2 and UNI...

The following slide deck was published by Allogene Therapeutics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Allogene Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation

Clinical-stage biotech SpringWorks Therapeutics ( NASDAQ: SWTX ) lost ~21% Wednesday, the sharpest intraday decline since May after its partner Allogene ( ALLO ) said that the company’s lead candidate nirogacestat would not be used in dose expansion cohorts in a...